888-969-2592
Kalkine 0
countryflagCA

Bausch Health Companies Inc

Healthcare CA BHC

9.42CAD
-0.02(0.21%)

Last update at 2025-07-04T16:34:00Z

Day Range

9.409.57
LowHigh

52 Week Range

5.4513.74
LowHigh

Fundamentals

  • Previous Close 9.44
  • Market Cap3133.78M
  • Volume39180
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA3089.00M
  • Revenue TTM9731.00M
  • Revenue Per Share TTM26.39
  • Gross Profit TTM 6888.00M
  • Diluted EPS TTM-0.16

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -129.00000M -1024.00000M -934.00000M -1837.00000M -4154.00000M
Minority interest -13.00000M -11.00000M 70.00M 73.00M 82.00M
Net income -212.00000M -937.00000M -559.00000M -1783.00000M -4148.00000M
Selling general administrative 2625.00M 2624.00M 2367.00M 2554.00M 2473.00M
Selling and marketing expenses - - - - -
Gross profit 5760.00M 6040.00M 5778.00M 6251.00M 6029.00M
Reconciled depreciation 1394.00M 1375.00M 1825.00M 2075.00M 2819.00M
Ebit 1370.00M 1210.00M 676.00M -73.00000M -2473.00000M
Ebitda 2585.00M 2585.00M 2518.00M 1824.00M 346.00M
Depreciation and amortization 1215.00M 1375.00M 1842.00M 1897.00M 2819.00M
Non operating income net other - - - - -
Operating income 1370.00M 1210.00M 676.00M -73.00000M -2384.00000M
Other operating expenses 6768.00M 7231.00M 6713.00M 8686.00M 7882.00M
Interest expense 1464.00M 1426.00M 1534.00M 1612.00M 1685.00M
Tax provision 83.00M -87.00000M -375.00000M -54.00000M -10.00000M
Interest income 1458.00M 1412.00M 13.00M 1592.00M 1651.00M
Net interest income -1450.00000M -1419.00000M -1521.00000M -1600.00000M -1674.00000M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 83.00M -87.00000M -375.00000M -54.00000M -10.00000M
Total revenue 8124.00M 8434.00M 8027.00M 8601.00M 8380.00M
Total operating expenses 4404.00M 4837.00M 4464.00M 6336.00M 5531.00M
Cost of revenue 2364.00M 2394.00M 2249.00M 2350.00M 2351.00M
Total other income expense net -1499.00000M -2234.00000M -1610.00000M -1764.00000M -1770.00000M
Discontinued operations - - - - -
Net income from continuing ops -212.00000M -937.00000M -559.00000M -1783.00000M -4144.00000M
Net income applicable to common shares -225.00000M -948.00000M -560.00000M -1788.00000M -4148.00000M
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 26523.00M 27350.00M 25686.00M 29202.00M 31199.00M
Intangible assets 5551.00M 6456.00M 5800.00M 6948.00M 8445.00M
Earning assets - - - - -
Other current assets 838.00M 1092.00M 776.00M 720.00M 855.00M
Total liab 26845.00M 27432.00M 25426.00M 29236.00M 30594.00M
Total stockholder equity -1279.00000M -1022.00000M -692.00000M -106.00000M 535.00M
Deferred long term liab - - - - -
Other current liab 1037.00M 1041.00M 2988.00M 4791.00M 4576.00M
Common stock - 10423.00M 10391.00M 10317.00M 10227.00M
Capital stock 10490.00M 10423.00M 10391.00M 10317.00M 10227.00M
Retained earnings -9824.00000M -9778.00000M -9186.00000M -8961.00000M -8013.00000M
Other liab - - 967.00M 1170.00M 1529.00M
Good will 11087.00M 11183.00M 11547.00M 12457.00M 13044.00M
Other assets - - 2271.00M 2345.00M 2542.00M
Cash 1181.00M 947.00M 564.00M 582.00M 605.00M
Cash and equivalents - - 564.00M 582.00M 605.00M
Total current liabilities 6752.00M 4302.00M 3941.00M 5198.00M 4913.00M
Current deferred revenue - 2092.00M - - -
Net debt 20435.00M 21441.00M 20202.00M 22072.00M 23320.00M
Short term debt - 450.00M 432.00M 0.00000M 1234.00M
Short long term debt 2674.00M 450.00M 432.00M - -
Short long term debt total - 22388.00M 20766.00M 22654.00M 23925.00M
Other stockholder equity - 214.00M 159.00M 462.00M 454.00M
Property plant equipment - - 1821.00M 1845.00M 1826.00M
Total current assets 5774.00M 5596.00M 4247.00M 5607.00M 5342.00M
Long term investments - - - - -
Net tangible assets - - -18039.00000M -19511.00000M -20954.00000M
Short term investments - - - - -
Net receivables 2140.00M 1998.00M 1790.00M 1775.00M 1577.00M
Long term debt 18942.00M 21938.00M 20334.00M 22654.00M 23925.00M
Inventory 1595.00M 1544.00M 1090.00M 993.00M 1094.00M
Accounts payable 656.00M 719.00M 521.00M 407.00M 337.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - -1881.00000M -2056.00000M -1924.00000M -2133.00000M
Additional paid in capital - - - - -
Common stock total equity - - - - 10227.00M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 363.00M 307.00M 326.00M 340.00M 664.00M
Deferred long term asset charges - - - - -
Non current assets total 20749.00M 21754.00M 21439.00M 23595.00M 25857.00M
Capital lease obligations - - - - -
Long term debt total - - 20334.00M 22654.00M 23925.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -303.00000M -4.00000M -261.00000M -419.00000M -196.00000M
Change to liabilities -75.00000M 121.00M -471.00000M -149.00000M -121.00000M
Total cashflows from investing activities -303.00000M 409.00M -261.00000M -419.00000M -196.00000M
Net borrowings -1010.00000M -1340.00000M -2187.00000M 1554.00M -1160.00000M
Total cash from financing activities -474.00000M -1513.00000M -2294.00000M 1443.00M -1353.00000M
Change to operating activities -66.00000M -4.00000M 12.00M 1.00M -72.00000M
Net income -212.00000M -937.00000M -559.00000M -1783.00000M -4144.00000M
Change in cash -1528.00000M 303.00M -1428.00000M 2521.00M -74.00000M
Begin period cash flow 2119.00M 1816.00M 3244.00M 723.00M 797.00M
End period cash flow 591.00M 2119.00M 1816.00M 3244.00M 723.00M
Total cash from operating activities -728.00000M 1426.00M 1111.00M 1501.00M 1501.00M
Issuance of capital stock 675.00M - - - -
Depreciation 1394.00M 1552.00M 1825.00M 2075.00M 2819.00M
Other cashflows from investing activities -35.00000M 27.00M 23.00M 23.00M 23.00M
Dividends paid - - - - -
Change to inventory -198.00000M -16.00000M -77.00000M -209.00000M -5.00000M
Change to account receivables -57.00000M -229.00000M 170.00M 39.00M 216.00M
Sale purchase of stock 675.00M - - - 2.00M
Other cashflows from financing activities 6697.00M 1927.00M 3349.00M 5861.00M 8751.00M
Change to netincome -1600.00000M 895.00M 151.00M 1469.00M 2733.00M
Capital expenditures 268.00M 283.00M 309.00M 278.00M 235.00M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -396.00000M -128.00000M -366.00000M -318.00000M 18.00M
Stock based compensation 126.00M 128.00M 105.00M 102.00M 87.00M
Other non cash items -1464.00000M 1036.00M 581.00M 1655.00M 2865.00M
Free cash flow -996.00000M 1143.00M 802.00M 1223.00M 1266.00M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BHC
Bausch Health Companies Inc		 -0.02 0.21% 9.42 - 1.69 0.32 18.74 2.33 8.07
CRON
Cronos Group Inc		 0.01 0.36% 2.77 13.68 - 8.04 0.67 0.02 -1.9458
CURA
Curaleaf Holdings Inc.		 0.01 0.89% 1.14 - 138.89 0.62 0.72 1.00 5.90
GUD
Knight Therapeutics Inc.		 0.01 0.25% 6.04 60.30 80.65 1.61 0.76 1.27 6.84
TLRY
Tilray Inc		 -0.01 1.45% 0.68 - 1000.00 0.66 0.14 0.56 -2.299

Reports Covered

Stock Research & News

View All

Profile

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company, develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health in the United States and internationally. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; dermatology products; generic pharmaceutical products; and dentistry products. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Bausch Health Companies Inc

2150 St. ElzEar Boulevard West, Laval, QC, Canada, H7L 4A8

Key Executives

Name Title Year Born
Mr. Thomas J. Appio CEO & Director 1962
Mr. Thomas G. Vadaketh Exec. VP & CFO 1963
Mr. Mirza Dautbegovic Sr. VP & COO NA
Mr. John S. Barresi Sr. VP, Controller & Chief Accounting Officer 1973
Dr. Robert F. Butz VP of Medical & Scientific Affairs NA
Mr. Arthur J. Shannon Sr. VP and Head of Investor Relations & Global Communications NA
Ms. Seana Carson Exec. VP & Gen. Counsel 1972
Ms. Kathleen Fitzpatrick Sr. VP & Chief HR Officer NA
Dr. Tage Ramakrishna M.D. Chief Medical Officer and Pres of R&D 1974
Mr. Jeff Hartness Sr. VP of Market Access, Commercial Operations & Gov. Affairs NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.